Published on 12 December 2016
Strategies used to delay or prevent access to affordable generic drugs in the US
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.051
4.983 views
Published on 12 December 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.051
4.983 views
Published on 31 October 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.049
4.105 views
Published on 31 October 2016
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2016.0504.048
6.939 views
Published on 31 October 2016
2.516 views
Published on 26 October 2016
Author(s): Beat Flühmann, PhD, Jon SB de Vlieger, PhD, Professor Gerrit Borchard, PharmD, PhD, Professor Stefan Mühlebach, PhD, Sesha Neervannan, PhD, Vinod P Shah, PhD
complex drug products, EMA, generics, harmonization, non-biological complex drug (NBCD), therapeutic equivalence, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2016.0503.026
7.115 views
Published on 26 October 2016
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2016.0503.025
3.144 views
Published on 26 October 2016
Author(s): Brendan T Griffin, PhD, Frank Hallinan, PhD, J Michael Morris, PhD, Joan O’Callaghan, BSc Pharm, Margaret Bermingham, PhD, Sean Barry, PhD, Una Moore, PhD
biological medicines, biosimilar, Health Products Regulatory Authority, regulatory science, Regulatory Science Ireland
DOI: 10.5639/gabij.2016.0504.043
9.364 views
Published on 26 October 2016
Author(s): Adjunct Professor Pekka Kurki, MD, PhD
automatic substitution, FDA guidelines, global reference product, information, interchangeability, regulatory harmonization
DOI: 10.5639/gabij.2018.0702.011
7.805 views
Published on 26 October 2016
Author(s): Amit Garg, MD, Shyam Akku, MD, Suhas Khandarkar, MPharm
anticancer drugs, cost-minimization, generics, pharmacoeconomics
DOI: 10.5639/gabij.2016.0504.042
15.760 views
Published on 26 October 2016
Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
ASBM, biologicals, biosimilars, labelling, naming, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2016.0504.040
9.064 views
Published on 26 October 2016
Author(s): Adjunct Professor Pekka Kurki, MD, PhD
biosimilars, NOR-SWITCH, totality of evidence
DOI: 10.5639/gabij.2016.0504.039
6.385 views
Published on 26 October 2016
Author(s): Nada Moustafa Abdel Rida, MSc Candidate, Professor Mohamed Izham Mohamed Ibrahim, PhD
developing countries, external reference pricing, government strategies, medicines, pharmaceutical pricing policy, price containment
DOI: 10.5639/gabij.2017.0601.002
9.547 views